Phase 3, randomized, double-blind, placebo controlled study of venetoclax combined with azacitidine versus azacitidine in treatment-naive patients with acute myeloid leukemia.

被引：5
|
作者：
Potluri, Jalaja
Xu, Tu
Hong, Wan-Jen
Mabry, Mack H.
机构：
[1] AbbVie Inc, Chicago, IL USA
[2] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS7069
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7069
引用
收藏
页数：5
相关论文
共 50 条
  • [21] A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia
    Murthy, Guru Subramanian Guru
    Saliba, Antoine N.
    Szabo, Aniko
    Harrington, Alexandra
    Abedin, Sameem
    Carlson, Karen
    Michaelis, Laura
    Runaas, Lyndsey
    Baim, Arielle
    Hinman, Alex
    Maldonado-Schmidt, Sonia
    Venkatachalam, Annapoorna
    Flatten, Karen S.
    Peterson, Kevin L.
    Schneider, Paula A.
    Litzow, Mark
    Kaufmann, Scott H.
    Atallah, Ehab
    HAEMATOLOGICA, 2024, 109 (09) : 2864 - 2872
  • [22] Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.
    Dohner, Hartmut
    Montesinos, Pau
    Polo, Susana Vives
    Zarzycka, Ewa
    Wang, Jianxiang
    Bertani, Giambattista
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    Burguera, Adolfo de la Fuente
    Cerchione, Claudio
    Daigle, Scott
    Hui, Jianan
    Pandya, Shuchi Sumant
    Gianolio, Diego A.
    Recher, Christian
    De Botton, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia
    Manda, Sudhir
    Anz III, Bertrand M.
    Benton, Christopher
    Broun, E. Randolph
    Yimer, Habte A.
    Renshaw, John S.
    Geils Jr, George
    Berdeja, Jesus
    Cruz, Jose
    Melear, Jason M.
    Fanning, Suzanne
    Fletcher, Luke
    Li, Yukun
    Duan, Yinghui
    Werner, Michael E.
    Potluri, Jalaja
    Pai, Madhavi V.
    Donnellan, William B.
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (03)
  • [24] Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
    Garciaz, Sylvain
    Hospital, Marie-Anne
    Alary, Anne-Sophie
    Saillard, Colombe
    Hicheri, Yosr
    Mohty, Bilal
    Rey, Jerome
    D'Incan, Evelyne
    Charbonnier, Aude
    Villetard, Ferdinand
    Maisano, Valerio
    Lombardi, Laura
    Ittel, Antoine
    Mozziconacci, Marie-Joelle
    Gelsi-Boyer, Veronique
    Vey, Norbert
    CANCERS, 2022, 14 (08)
  • [25] Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
    Garciaz, Sylvain
    Dumas, Pierre-Yves
    Bertoli, Sarah
    Sallman, David A.
    Decroocq, Justine
    Belhabri, Amine
    Orvain, Corentin
    Requena, Gaspar Aspas
    Simand, Celestine
    Laribi, Kamel
    Carre, Martin
    Santagostino, Alberto
    Himberlin, Chantal
    Peterlin, Pierre
    Bonnet, Sarah
    Chan, Onyee
    Lancet, Jeffrey
    Komrokji, Rami
    Vergez, Francois
    Chapuis, Nicolas
    Raskovalova, Tatiana
    Plesa, Adriana
    Lhoumeau, Anne-Catherine
    Mineur, Ariane
    Hospital, Marie Anne
    Pigneux, Arnaud
    Vey, Norbert
    Recher, Christian
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (10) : 1870 - 1876
  • [26] Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia.
    Manda, Sudhir
    Anz, Bertrand Marquess
    Benton, Christopher
    Broun, E. Randolph
    Yimer, Habte Aragaw
    Melear, Jason M.
    Cruz, Jose C.
    Fanning, Suzanne
    Sharman, Jeff Porter
    Kang, Kingston
    Svensson, Anders
    Pai, Madhavi
    Geils, George F.
    Renshaw, John Scott
    Donnellan, William Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naive or relapsed or refractory acute myeloid leukemia.
    Wang, Huafeng
    Wei, Xudong
    Liang, Yang
    Jiang, Qian
    He, Wenjuan
    Li, Qiubai
    Weng, Jianyu
    Chen, Suning
    Chang, Chunkang
    Ma, Hongbing
    Xu, Yajing
    He, Qun
    Chen, Zi
    Liu, Lihui
    Men, Lichuang
    Cong, Danhua
    Zhang, Zhang
    Yang, Dajun
    Zhai, Yifan
    Jin, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] A Real World Study of Venetoclax Combined with Azacitidine in 64 Chinese Patients Newly Diagnosed Acute Myeloid Leukemia
    Qian, Jiejing
    Xu, Jieyu
    Hong, Qing
    Lou, Yinjun
    Mao, Liping
    Xu, Weilai
    Yang, Min
    Yu, Wenjuan
    Meng, Haitao
    Mai, Wenyuan
    Ye, Xiujing
    Zhu, Honghu
    Jin, Jie
    BLOOD, 2021, 138
  • [29] Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients
    Petit, C.
    Saillard, C.
    Mohty, B.
    Hicheri, Y.
    Villetard, F.
    Maisano, V.
    Charbonnier, A.
    Rey, J.
    D'Incan, E.
    Rouzaud, C.
    Gelsi-Boyer, V.
    Murati, A.
    Lhoumeau, A. C.
    Ittel, A.
    Mozziconacci, M. J.
    Alary, A. S.
    Hospital, M. -A.
    Vey, N.
    Garciaz, S.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (04) : 530 - 537
  • [30] Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients
    Miklos, Egyed
    Oliver, Toth Peter
    Adam, Kellner
    Eva, Karadi
    Balazs, Kollar
    Eszter, Kovacs
    Anett, Pavlovics
    Viktoria, Gyori-Korom
    Jozsef, Herczeg
    Peter, Rajnics
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (02) : 183 - 189
12345